Literature DB >> 15320992

Drug resistance testing provides evidence of the globalization of HIV type 1: a new circulating recombinant form.

Manuel Gómez-Carrillo1, Jorge F Quarleri, Andrea E Rubio, Mauricio G Carobene, Darío Dilernia, Jean K Carr, Horacio Salomón.   

Abstract

To monitor HIV-1 diversity in Argentina, a phylogenetic-based analysis of HIV-1 partial pol sequences obtained for resistance testing in 587 treatment failure patients was performed in Buenos Aires city between 2001 and 2003. HIV-1 RNA was isolated from plasma samples and partial pol fragments amplified by RT-PCR. Sequences were obtained by automated sequencing. Phylogenetic analysis was performed and recombination patterns characterized. A total of 299 sequences grouped into clade B (50.94%) and 284 were B/F recombinants (48.38%). Four sequences were grouped into clades A, C, and F (0.68%). The clade C sample, 96105, was found to be a BC recombinant and samples 103396 and 104575 showed the same mosaic pattern with Kisii5009 from Kenya and 97KR004 from Korea, previously described as A2D recombinants. With the presence of two full-length genomes, one from Kenya and one from Korea, and now two partial genomes from Argentina, this recombinant is designated CRF16_A2D. Its presence on three continents shows that CRF16_A2D has a global distribution.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15320992     DOI: 10.1089/0889222041725172

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  Drug resistance mutations in HIV pol sequences from Argentinean patients under antiretroviral treatment: subtype, gender, and age issues.

Authors:  Leandro R Jones; Franco Moretti; Andrea Y Calvo; Darío A Dilernia; Julieta M Manrique; Manuel Gómez-Carrillo; Horacio Salomón
Journal:  AIDS Res Hum Retroviruses       Date:  2011-11-22       Impact factor: 2.205

2.  The Use of Bioinformatics for Studying HIV Evolutionary and Epidemiological History in South America.

Authors:  Gonzalo Bello; Marcelo A Soares; Carlos G Schrago
Journal:  AIDS Res Treat       Date:  2011-11-15

3.  Longitudinal characterization of HIV-1 pol-gene in treatment-naïve men-who-have-sex-with-men from acute to chronic infection stages.

Authors:  Cintia Cevallos; Andrés C A Culasso; Carlos Modenutti; Ana Gun; Omar Sued; María M Avila; Diego Flichman; M Victoria Delpino; Jorge Quarleri
Journal:  Heliyon       Date:  2020-12-07

4.  An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1.

Authors:  Sergei L Kosakovsky Pond; David Posada; Eric Stawiski; Colombe Chappey; Art F Y Poon; Gareth Hughes; Esther Fearnhill; Mike B Gravenor; Andrew J Leigh Brown; Simon D W Frost
Journal:  PLoS Comput Biol       Date:  2009-11-26       Impact factor: 4.475

5.  Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1.

Authors:  Robert J Gifford; Tulio de Oliveira; Andrew Rambaut; Oliver G Pybus; David Dunn; Anne-Mieke Vandamme; Paul Kellam; Deenan Pillay
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

6.  The Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006.

Authors:  Erik Billings; Eric Sanders-Buell; Meera Bose; Andrea Bradfield; Esther Lei; Gustavo H Kijak; Miguel A Arroyo; Rukia M Kibaya; Paul T Scott; Monique K Wasunna; Frederick K Sawe; Douglas N Shaffer; Deborah L Birx; Francine E McCutchan; Nelson L Michael; Merlin L Robb; Jerome H Kim; Sodsai Tovanabutra
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

7.  Genomic characterization and molecular evolution analysis of subtype B and BF recombinant HIV-1 strains among Argentinean men who have sex with men reveal a complex scenario.

Authors:  Cintia G Cevallos; Leandro R Jones; Maria A Pando; Jean K Carr; Maria M Avila; Jorge Quarleri
Journal:  PLoS One       Date:  2017-12-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.